Back to searchBackground Papers2
Result Papers0
Derived Papers0
NIvolumab COmbination With Standard First-line Chemotherapy and Radiotherapy in Locally Advanced Stage IIIA/B Non-Small Cell Lung Carcinoma
NCT02434081
PHASE2INTERVENTIONAL
ETOP IBCSG Partners Foundation
94 participants
Started 2015-11-25 · Completed 2020-03-31
Status: Completed (as of 12-23-2025)
Conditions
Non-small Cell Lung Cancer Stage III
Interventions
Linked Papers (from SciSciNet-V2)
Total Papers2
Background
1Result
0Derived
0Unknown
1Total Citations Per Year
Brief Summary
The aim of the study is to investigate the tolerability (how severe the side effects are) and the efficacy (how well the treatment works) when nivolumab is added to the current standard treatment (chemotherapy and radiotherapy) given to patients with advanced NSCLC.
Sort by:
Background Papers2
Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial
2017
951 citations
Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial
2017
951 citations
Result Papers0
No result papers linked
Derived Papers0
No derived papers linked